BPC-157: a large reputation resting on three human pilot studies

Start here

BPC-157 is a synthetic chain of fifteen amino acids, copied from part of a protein found in human gastric juice. Its name — Body Protection Compound 157 — comes from that origin, and "cytoprotective", meaning cell-protecting, is the word the literature uses most often for what it does.

What it is best documented doing is helping build new blood vessels. In cell and animal studies it raises the activity of a receptor called VEGFR2 that blood-vessel cells use to sprout new vessels, and switches on the signalling chain beneath it ^[8]. New vessels arrive early in repair, well before there is any matrix worth remodeling, which is why this compound belongs at the front of the sequence rather than the end.

The gap between how confidently BPC-157 is discussed and what has actually been measured in people is the widest on this site. This page states that gap plainly instead of working around it, because on current evidence it is the most important thing about the compound.

What BPC-157 is

BPC-157 is a synthetic fifteen-amino-acid peptide — glycine, glutamic acid, proline, proline, proline, glycine, lysine, proline, alanine, aspartic acid, aspartic acid, alanine, glycine, leucine, valine — derived from a partial sequence of the human gastric juice protein BPC. Its molecular formula is C62H98N16O22.

It is described as a stable gastric pentadecapeptide, and the stability claim is about resisting breakdown in gastric juice rather than about lasting long in the bloodstream, where it does not.

It is not a growth hormone and it is not a growth-hormone secretagogue, despite the company it keeps in peptide discussion. One reported mechanism does touch that system — in cultured tendon cells it increased growth-hormone-receptor signalling — but the peptide itself is a fifteen-residue fragment of a protective gastric protein, not a hormone.

It also travels under a number of research designations: pentadecapeptide BPC 157, BPC 157, PL 14736, PLD-116, PL-10 and bepecin. Under any of them it is not an approved medicine anywhere in the world, and it is distributed for laboratory research use only.

Where it acts in the repair sequence

The repair effects reported for BPC-157 in animals are most consistently linked to angiogenesis — the growth of new blood vessels — which places it at the opening phase of repair.

The best-characterised route is the VEGF receptor 2 pathway. BPC-157 up-regulates VEGFR2 expression and promotes its internalisation in vascular endothelial cells, with downstream activation of VEGFR2-Akt-eNOS signalling, the last step of which involves endothelial nitric oxide synthase ^[8]. The reported result is greater vessel density in cell and animal models, and faster blood-flow recovery in ischaemic muscle; blocking endocytosis abolished the effect.

Several additional routes appear in the literature: the FAK-paxillin complex, associated with cell migration; sensitisation of the growth hormone receptor in tendon fibroblasts; and modulation of the nitric-oxide system and of several neurotransmitter systems, which is where the reported gut and mood observations tend to be traced.

That combination — a vascular signal plus broad cytoprotection — explains why the animal literature spans such different tissues: gastric mucosa, tendon, ligament, gut. It is one mechanism applied at the point in repair where every tissue needs the same thing first, which is a blood supply and cells that survive the initial insult.

What it is not is a remodeling signal in the strict sense. Nothing in the documented mechanism describes cross-linking matrix or governing metalloproteinase balance; that work belongs to GHK-Cu, further down the sequence.

What the studies measured

Gastric mucosa. The foundational cytoprotection finding is an ulcer study in Wistar rats: BPC 157 reduced gastric ulcer area and accelerated healing, with an ulcer-formation inhibition ratio of 45.7% to 65.6% at the higher doses used, accelerated rebuilding of the glandular epithelium and increased granulation-tissue formation; intramuscular delivery outperformed intragastric ^[14]. Granulation tissue and epithelial rebuilding are repair-sequence vocabulary, and this is where the compound's reputation began.

Tendon. BPC 157 accelerated healing of a fully transected rat Achilles tendon across biomechanical, functional, microscopic and macroscopic measures, and stimulated tendocyte outgrowth in culture ^[10]. Improved biomechanical and functional recovery against untreated controls is the single most-cited animal result behind the compound's connective-tissue reputation.

Vessels. The VEGFR2 work spans chick chorioallantoic membrane, rat hind-limb ischaemia and human vascular endothelial cells, with increased vessel density in vivo and in vitro ^[8].

Pharmacokinetics. The first formal characterisation, in rats and dogs, found linear pharmacokinetics, an elimination half-life under thirty minutes, intramuscular bioavailability of roughly 14-19% in rats and 45-51% in dogs, rapid breakdown into small peptide fragments entering ordinary amino-acid metabolism, and excretion via urine and bile ^[13]. That half-life raises a question the literature has not answered: a molecule cleared that quickly cannot be present across the weeks over which tendon or gut healing is reported to improve, so whatever it contributes must be initiated early and then carried forward by the tissue itself.

Humans. One first-in-human intravenous safety pilot has been published. Intravenous BPC157 at up to 20 mg was given to two healthy adults — a 58-year-old man and a 68-year-old woman — and was well tolerated, with no observed adverse events and no measurable changes in cardiac, hepatic, renal, thyroid or glucose biomarkers ^[12]. It is a safety signal from a sample of two, and it is not an efficacy trial.

Reputation versus record

BPC-157 is the most-discussed compound on this desk and the least-evidenced in humans. Those two facts are worth stating in the same breath rather than in different sections.

The human record, in full, is three pilot studies. A 2025 narrative review counted them: one in intraarticular knee pain, one in interstitial cystitis, and one intravenous safety and pharmacokinetic study. No adverse effects were reported in any of them, and no rigorous large-scale trial exists. The review's conclusion is unambiguous — BPC-157 should be considered investigational, and its use approached with caution ^[7]. The intravenous study is the third of those three, and it enrolled two people ^[12].

Everything else is rodent, dog or cell-culture work: the tendon result ^[10], the ulcer healing ^[14], the angiogenic mechanism ^[8], the pharmacokinetics ^[13]. Animal repair results are genuine findings about animals. They are not proven benefits in people, and the honest position is that the balance of benefit and risk in humans is unknown rather than favourable.

Three further qualifiers belong here. A large share of the foundational literature comes from a single research group and its collaborators, so independent replication is limited — newer reviewers flag this explicitly. Because the compound moves through non-regulated channels, the identity, purity and actual content of any given product are unverified outside formal studies. And several claims that circulate widely — weight loss, muscle building, raised testosterone — are not supported by the published evidence at all.

A 2026 review of approved and unapproved peptide therapies for musculoskeletal conditions arrives at the same place from a wider angle: favourable tissue-repair outcomes in animal models, scarce rigorous human safety data, and real potential for serious harm in a category operating largely outside regulatory oversight ^[6].

What users report — and what the safety record says

What follows first is community-reported material: anecdotal, not clinical evidence. It is drawn from user forums, clinic write-ups and published summaries of online reports, and it carries no verified dose. Given how thin the human trial record is, this material is doing more work in BPC-157's reputation than it can honestly bear — which is a reason to read it carefully, not a reason to omit it.

Faster recovery from tendon, ligament and joint injuries is the main reason people in research-use communities describe trying it: stubborn problems such as tennis elbow, rotator-cuff strains and old sprains feeling more usable, often within the first one to three weeks. Reduced joint stiffness and easier painful movements are frequently described on a similar timescale. Improved digestive symptoms come up nearly as often — less bloating, cramping and urgency, and better tolerance of foods that previously caused trouble — which people connect to the peptide's gastric origin, and which gastroenterologists point out has no controlled human trial behind it. A general sense of reduced inflammation, faster closing of minor skin wounds, and better sleep, mood or stress tolerance are each reported occasionally, and commentators note how easily those overlap with relief from pain or gut symptoms, or with placebo.

The reported downsides are mostly local and minor. Injection-site redness, brief stinging or a small raised bump is the most common, usually described as fading within an hour and gone within a day. Mild nausea, loose stools or stomach cramping is reported by a minority, more often with oral or sublingual products than with injection. Fatigue in the first week, mild headache, and brief dizziness or lightheadedness shortly after a dose are each occasionally described. Transient flushing or warmth within about half an hour is reported and linked by users to the peptide's effects on blood-vessel tone. Rarely, palpitations or a racing feeling are mentioned; commentators treat persistent rapid heartbeat, chest pain or marked blood-pressure change as reasons to stop and seek medical evaluation.

The documented cautions sit at a different level of seriousness. The first is the evidence base itself: almost everything known comes from rodent studies, and the true balance of benefit and risk in humans has not been established ^[7][12]. The second is angiogenesis — the same pro-vessel activity that underlies the repair results, running through VEGFR2 and the nitric-oxide system, is a theoretical concern for anyone with an active or suspected cancer, since tumours also depend on new vessels ^[8]. The third is a mechanism-based interaction question: in rodent work BPC-157 alters brain serotonin activity, which raises an unresolved theoretical concern about combining it with serotonin-raising medicines. The fourth is growth signalling — increased growth-hormone-receptor signalling in cultured tendon cells is part of how repair is thought to be driven, and no long-term human data exist to settle what that means over time. It is prohibited in sport at all times. And it is untested in pregnancy, breastfeeding and children, where the reasonable position is avoidance rather than extrapolation.

Where BPC-157 sits in the repair timeline

BPC-157 opens the sequence. Its documented contribution is vascular and cytoprotective — get blood to the site, keep cells alive through the insult — which is the precondition for everything the later stations do rather than a substitute for them.

That position also explains why it appears inside the GLOW blend: a matrix-building peptide with no blood supply beneath it has nothing to build on. As a combination rationale that is coherent, and it remains untested.

What has to travel with all of it is the evidence statement. Three human pilot studies, one of them with two participants, against a rodent literature deep enough to have convinced a very large number of people ^[7][12]. The compound may well do in humans some part of what it does in rats. That case has simply not been made yet, and the comparison page sets the size of that gap against the other two entries here.